Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants (C-015-404)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01861730
Recruitment Status : Completed
First Posted : May 24, 2013
Last Update Posted : April 9, 2018
Statens Serum Institut
Sanofi Pasteur, a Sanofi Company
National Institute of Allergy and Infectious Diseases (NIAID)
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Information provided by (Responsible Party):

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : December 22, 2017
  Actual Study Completion Date : December 22, 2017